Zoetis Inc Q3 2020 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: David Michael Westenberg - Guggenheim Securities, LLC, Research Division - Analyst : Congrats on a good quarter. So on Trio, at least from our research, we're not seeing any competitive entrants yet and spring is a half year way, VMX is coming up in 2 months. Is there any -- can you help us think about the difference in your -- in the Trio peak sales expectation in the event the competitor doesn't launch until after the spring? And then as a follow-up to Trio, you now have had a full season of it. Are you seeing more adoption from heartworm customers or maybe legacy tick-and-flea prescribers only? And kind of what I'm trying to get at that is essentially there is regional differences in prescribing behavior and I'm just trying to figure out, again, market size question on Trio.

Question: Ekaterina V. Knyazkova - JPMorgan Chase & Co, Research Division - Analyst : This is actually Ekaterina on for Chris. And the first question is you've touched upon this, but should we be thinking about the durability of some of the COVID-19 tailwinds that we've seen in U.S. companion like rising pet adoptions and increasing standard of care per visit? Do you think that this is something that reverses as those people come back into the office and don't spend as much time with their pets? Or is this something that can be more durable as you think about 2021 and beyond? And then the second question is on International -- on the International companion business. So with some of the recent lockdown orders across Europe, what are you seeing on the ground in terms of any initial data points on clinic visits and foot traffic and things like that? How should we be thinking about the trajectory of the International companion business relative to what we saw with the first wave of COVID-19 lockdowns?